Call Today for a FREE Case Consultation
Girardi Keese 800.401.4530

Glaxo, other large pharmaceuticals, continue to commit fraud

Forbes recently published an interesting article titled "Is Big Pharma Addicted To Fraud?" Author Erika Kelton discussed the fraudulent ways pharmaceutical companies, such as GlaxoSmithKline, sell their products, including using bribery, falsified research and illegal marketing tactics.

Glaxo, a pharmaceutical company that manufactures a number of drugs, including type 2 diabetes drug Avandia, has been accused of fraud on numerous occasions by multiple governments. Most recently, Chinese authorities investigated the company for allegedly using a Shanghai travel agency to funnel bribes. The company has also been under scrutiny for:

  • Improperly conducting research at its Shanghai development center
  • Marketing prescription drugs for unapproved treatments
  • Providing kickbacks to companies and individuals who promote Glaxo's sales

The U.S. government has policed Glaxo and other pharmaceutical companies for failing to put patient safety first, and using improper marketing and sales tactics. That policing effort, however, has not been enough. Pharmaceutical companies like Glaxo continue to put profits above safety, and now other countries have begun to speak up against its actions. As the Chinese Public Security Ministry official said, "I need to remind foreign pharmaceutical companies that, because they occupy a leading position in the industry and reap huge amounts of commercial profits, they should also bear a great responsibility to society and the public."

Individuals who have been injured by Glaxo or another pharmaceutical company can also take action to hold the company accountable and push for safety reforms. Through a pharmaceutical liability claim, injured individuals can recover compensation for their injuries while saying, "We will not accept corporate fraud."

Source: Forbes, "Is Big Pharma Addicted To Fraud?" Erika Kelton, July 29, 2013

No Comments

Leave a comment
Comment Information
FindLaw Network

Privacy Policy | Business Development Solutions by FindLaw, a Thomson Reuters business.